Antibody Discovery: Sequence Liabilities

This video guide demonstrates how to de-risk your antibody candidates by assessing potential sequence liabilities using the Antibody Sequence Liabilities block on Platforma. We walk you through configuring the analysis, interpreting the risk assessment results, and using this critical data to select the most promising, stable, and manufacturable leads for downstream development. In this video, you will learn how to: Screen antibody sequences for common liabilities like deamidation, isomerization, oxidation, and N-linked glycosylation. Configure the analysis by selecting specific liability motifs to assess. Interpret the results table, which provides overall, framework (FR), and CDR-specific risk scores. Visualize liability data on a Clonotype Space UMAP plot to see how risk is distributed across your sequence landscape. Combine liability risk with enrichment data to identify top-tier candidates that are both highly enriched and liability-free. Integrate liability assessment into your antibody picking and selection workflow. Platforma is a no-code, end-to-end bioinformatics platform designed to empower biologists and immunologists to get from raw data to publication-ready discoveries without coding expertise. ➡️ Explore Platforma for antibody discovery: https://platforma.bio ➡️ Read our Documentation on Antibody Discovery: https://docs.platforma.bio/guides/ant...